Zelira Therapeutics Ltd (ASX:ZLD) managing director Richard Hopkins speaks to Proactive’s Andrew Scott at the virtual ASX Small and Mid-Cap Conference 2020.
The medicinal cannabis company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.
The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.
Price: 0.077 AUD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
Zelira Therapeutics Ltd's (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Richard Hopkins and Emyria Ltd's (ASX:EMD) Michael Winlo speak to Proactive's Andrew Scott after announcing they've entered into an agreement to conduct an observational trial for patients diagnosed with autism spectrum disorder (ASD)...
Mining
Mining
Health
Prev article
